John Bigelow, Jun 27, 2012
Cases involving pharmaceuticals settlements to patent litigation with so called “reverse payments” or, as the FTC now prefers to call them, “exclusion payments” have been a source of controversy for some time. The FTC has been fighting these agreements since 2000 on the antitrust grounds that they are agreements between horizontal competitors not to compete. Although the FTC had some early successes, the issue is likely to be an increasing sourc
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.116.51.117
Please verify email or join us to access premium content!